Rezolute, Inc. current report, 24 July 2019

Full document

Rezolute, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Rezolute, Inc. on July 30, 2019, covering events occurring on July 24, 2019. The filing details the closing of a private placement of common stock and the exercise of call options by existing investors.

Key Financial Metrics

  • Gross Proceeds: Approximately $20.0 million raised from the issuance of common stock.
  • Shares Issued: An aggregate of 69,827,586 shares of common stock were issued in the offering.
  • Transaction Fees: The Company paid a 6% cash fee to co-lead agents (JMP Securities LLC and Canaccord Genuity LLC), totaling approximately $1.2 million.
  • Debt and Liquidity: The filing text does not provide specific values for total debt, cash balances, or liquidity ratios outside of the proceeds from this transaction.

Material Changes and Transaction Details

The Company completed an offering involving two primary components:

  1. Option Exercise: Handok, Inc. and Genexine, Inc. exercised call options to purchase 34,482,758 shares of common stock at $0.29 per share. This followed a prior agreement for Series AA Preferred Stock filed in January 2019.
  2. Additional Investment: Certain other accredited investors participated in the offering, contributing to the total share count and proceeds.

The transaction was exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The Company agreed to file a registration statement for the resale of these shares within 60 days of closing and seek effectiveness within 90 days.

Outlook, Risks, and Management Commentary

The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The primary contingency noted is the requirement to file a registration statement to permit the resale of the offering shares.

Key Facts for Investor Verification

  • Verify the dilution impact of issuing 69,827,586 new shares on existing shareholders.
  • Confirm the net cash proceeds after deducting the 6% underwriting fees and transaction costs.
  • Monitor the Company's compliance with the 60-day deadline to file the resale registration statement.
  • Review the full Purchase Agreement (Exhibit 10.1) for specific covenants and conditions attached to the investment.